The use of mushroom-forming fungi for the production of N-glycosylated therapeutic proteins.
The market for N-glycosylated therapeutic proteins represents multi-billion dollars in sales and is growing more than 10% each year. This requires cost-effective production platforms that display correct and homogeneous N-glycosylation. Based on recent results, we propose to use mushroom-forming basidiomycetes for the production of N-glycosylated therapeutic proteins.
Berends
Elsa
E
Molecular Microbiology and Kluyver Center for Genomics of Industrial Fermentations, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Scholtmeijer
Karin
K
Wösten
Han A B
HA
Bosch
Dirk
D
Lugones
Luis G
LG
D000363:Agaricales / Q000235:genetics / Q000378:metabolism*; D001688:Biological Products / Q000096:biosynthesis* / Q000235:genetics; D001709:Biotechnology / Q000379:methods; D006031:Glycosylation; D008954:Models, Biological; D030781:Organisms, Genetically Modified / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000235:genetics; D013678:Technology, Pharmaceutical / Q000379:methods
D001688:Biological Products; D011994:Recombinant Proteins